Clinical Trial Update: Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine hydrochloride with or without vismodegib in patients with recurrent or metastatic pancreatic cancer; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Vismodegib (Vismodegib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-02-13